Applying low disease activity criteria using the DAS28 to assess stability in patients with rheumatoid arthritis

H J M Vrijhoef, J P M Diederiks, C Spreeuwenberg, Sj Van der Linden

Objectives: To examine whether low disease activity criteria using the disease activity score (DAS28) can be applied to identify a reasonably large number of patients with stable low disease activity of rheumatoid arthritis (RA) over a six month period, with the ultimate intention of including these patients in a substitution based, shared care model. Additionally, to assess the reliability of the DAS28 for selecting patients with stable disease from an outpatient population.

Methods: Patients regularly seen at the rheumatology outpatient department of the university hospital Maastricht, were invited for assessment of the stability of their RA. The shared care model was intended to provide care to patients with stable, low disease activity of RA by nurse specialists. For this, patients underwent assessments using the DAS28 criteria at entry and three and six months later. Test-retest reliability was assessed for composing measures as well as for the DAS28.

Results: Of the 97 outpatients included, one third (31 patients) did not complete the study. Patients with missing data were older and assessed their disease activity as greater than patients with complete data. Applying the low disease activity criteria to assess stability over a period of six months (DAS28(T0)<3.2 and DAS28(T6)-DAS28(T0)≤1.2) resulted in identification of 22/56 (39%) patients with stable, low disease activity of RA. A good similarity score (intraclass correlation coefficient=0.82) for the DAS28 was found.

Conclusions: The low disease activity criteria using the DAS28 can be used to select patients with stable, low disease activity of RA from a rheumatic outpatient population.

Notwithstanding the consensus about which end points to measure when assessing disease activity (both core sets comprise process measures), the definition of rheumatic stability, as derived from subsequent measurements of rheumatic activity, still varies. Disease stability can be defined as the lack, within certain limits, of changes or fluctuations in parameters of a disease within a defined period of time. To assess disease stability a time component has to be included in the measure: based on subsequent measures of disease activity, the degree of disease stability can be assessed.

From the EULAR core set the so-called EULAR response criteria were derived, while criteria for improvement have been developed based on the ACR core set. The latter define change as a difference of 20% or more in subsequent measurements of tender and swollen joint counts and a difference of 20% or more in at least three out of five remaining measures. The EULAR response criteria make use of a disease activity score (DAS28) derived from four measures and, in addition to change in disease activity from baseline, also take the level of disease activity attained during follow up into account when defining response. When these definitions are considered within the context of assessing stability in this study, then low disease activity at baseline is also necessary. Otherwise, patients with severe RA are classified as having stable, low disease activity of RA and consequently not managed adequately. Thus, only the EULAR response criteria seem to be applicable in this case to assess stability, although they were not originally developed for this purpose. Although the use of these criteria to include patients has been advocated previously, no study has yet reported the results of this particular application.

Abbreviations: ACR, American College of Rheumatology; DAS28, disease activity score; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis.
This study examines whether low disease activity criteria using the DAS28 can be applied to identify a reasonably large number of patients with a stable low disease activity of RA over a six month period, with the ultimate intention of including these patients in a substitution based, shared care model.

PATIENTS AND METHODS

Patient selection

All patients who were receiving care by rheumatologists at the rheumatology outpatient department of the University Hospital Maastricht and known to have RA, according to the criteria of the ACR, were identified.

An explanatory letter with informed consent form and postage-free envelope were mailed to patients with RA. Only those patients were invited who had been referred by general practitioners willing to have a rheumatology nurse in their practice if the model were implemented in clinical practice after completion of this feasibility study. After having given their informed consent, patients were scheduled for assessment of disease activity by a rheumatology nurse in the outpatient department of the hospital. Three assessments were scheduled: at entry (T0), and three months (T3) and six months later (T6). Just before every assessment patients were sent a self report form and asked to complete this on the day of assessment and return it to the nurse. Three months was chosen as the interval between measurements of stability because this period of time is used by many doctors when seeing patients with stable chronic disease. Assessments were performed between April 1998 and February 1999.

Measures of disease activity

The number of swollen and the number of tender joints were both assessed by 28 joint counts. For this a mannequin, consisting of a stick figure drawing of a person with each joint indicated by a circle, was used. The rheumatology nurses marked the tender or swollen joint by ticking the appropriate circle, was used. The rheumatology nurses indicated by a circle, was used. The rheumatology nurses including these patients in a substitution based, shared care model.

### Table 1: Baseline characteristics of patients with complete measurements and of patients with missing measurements. Results are given as mean (SD) unless stated otherwise

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Complete measurements (n=66)</th>
<th>Missing measurements (n=31)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>62.7 (12.4)</td>
<td>68.6 (11.9)</td>
<td>0.030*</td>
</tr>
<tr>
<td>Sex (No (%) male)</td>
<td>29 (44)</td>
<td>17 (55)</td>
<td>0.316†</td>
</tr>
<tr>
<td>Tender joints</td>
<td>2.7 (3.2)</td>
<td>3.9 (4.4 [27]</td>
<td>0.165*</td>
</tr>
<tr>
<td>Swollen joints</td>
<td>3.3 (3.1)</td>
<td>4.1 (2.9 [28]</td>
<td>0.275*</td>
</tr>
<tr>
<td>ESR (mm/1st h)</td>
<td>18.3 (17.0 [63]</td>
<td>24.5 (25.0 [27]</td>
<td>0.176*</td>
</tr>
<tr>
<td>Global DA</td>
<td>3.0 (1.0) [62]</td>
<td>3.5 (0.9) [24]</td>
<td>0.035*</td>
</tr>
<tr>
<td>DAS28</td>
<td>2.9 (1.0) [63]</td>
<td>3.5 (1.0) [22]</td>
<td>0.050‡</td>
</tr>
</tbody>
</table>

Numbers in square brackets are the number of patients for whom data are available when case data were not available for the whole group.

*Student’s t test; †Pearson χ²; ‡Mann-Whitney U test; §global assessment of disease activity.

### Table 2: Intraclass correlation coefficient (ICC) for measurements of activity

<table>
<thead>
<tr>
<th>Measurement</th>
<th>N</th>
<th>T0*</th>
<th>T3†</th>
<th>T6‡</th>
<th>ICC</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tender joints</td>
<td>65</td>
<td>2.8</td>
<td>3.2</td>
<td>3.4</td>
<td>0.74</td>
<td>0.61 to 0.83</td>
</tr>
<tr>
<td>Swollen joints</td>
<td>65</td>
<td>3.4</td>
<td>2.8</td>
<td>2.7</td>
<td>0.80</td>
<td>0.70 to 0.87</td>
</tr>
<tr>
<td>ESR (mm/1st h)</td>
<td>60</td>
<td>18.6</td>
<td>20.4</td>
<td>22.5</td>
<td>0.94</td>
<td>0.91 to 0.96</td>
</tr>
<tr>
<td>Global DA</td>
<td>62</td>
<td>6.4</td>
<td>6.5</td>
<td>6.4</td>
<td>0.86</td>
<td>0.79 to 0.91</td>
</tr>
<tr>
<td>DAS28</td>
<td>56</td>
<td>3.0</td>
<td>3.2</td>
<td>3.2</td>
<td>0.82</td>
<td>0.72 to 0.89</td>
</tr>
</tbody>
</table>

*T0 measurement at start; †T3 measurement three months after start; ‡T6 measurement six months after start; §p<0.001; §global assessment of disease activity.
Comparison of groups with and without data at all measurements showed a statistically significant difference, in that older patients with missing data on average reported a higher mean score for both global assessment of disease activity and DAS28 (table 1). The presence of data at all measurements does not imply complete data. Moreover, for 56 patients complete data were available, while for 10 patients the score on one or more variables at one or more measurements was absent.

**Reliability of measurements for stability assessment**

Assessment of reliability of measurements at baseline and at three and six months showed moderate ICCs (0.6–0.8) for tender and swollen joints assessed by the nurse (table 2). Good ICCs (>0.8–0.9) were found for global assessment of disease activity, and DAS28, while a very good ICC (>0.9) was found for ESR.

**Measuring disease stability**

Applying the DAS28 showed low disease activity in 27/56 (48%) patients at baseline (table 3). The difference in DAS28 between baseline and the last measurement was ≤1.2 for 50/56 (89%) patients. At T6 18/56 (32%) patients could be classified as having stable, low disease activity of RA, while 11 (20%) patients had changed from medium to low disease activity of RA.

Four patients with low disease activity of RA at baseline did not change more than 1.2 DAS28 points, but had medium disease activity of RA six months after baseline measurement.

Between baseline and measurement at three months 52/56 (93%) did not change by more than 1.2 DAS28 points, and between baseline and the last measurement at six months 50/56 (89%) patients did not change by more than 1.2 DAS28 points (table 4). When the allowed change was set at 0.6 (one times the measurement error), these proportions were 79% (44/56) and 68% (38/56) respectively. Applying the low disease activity criteria, that is a DAS28 baseline score ≤3.2 and a difference ≤1.2 between DAS28 scores at baseline and the last measurement, resulted in stable low disease activity of RA in 22/56 (39) patients.

**DISCUSSION**

The disease activity of outpatients with RA was assessed on several occasions with the ultimate intention of including these patients in a shared care model. For this assessment, low disease activity criteria using the DAS28 were applied. The DAS28 is developed to measure a clinically relevant decrease in disease activity resulting from a treatment. In this study, however, the DAS28 was used for a different purpose—namely, to assess disease stability by defining stability as “the lack, within certain limits, of changes or fluctuations in parameters of a disease within a defined period of time”, where the “limits” were defined by the EULAR response criteria. Without the existence of a “gold standard” to assess stability in RA, interpretation of the findings of this study is not always unambiguous.

It was found that 22/56 (39%) patients could be classified as having stable, low disease activity of RA. The defined extent of change (1.2 DAS28 points) raises an important issue. A patient with an initial DAS28 of 3.2 at baseline and 4.4 at last follow up has, according to this change, stable RA while his/her index score increases between the first and last measurement by 37.5%. When the defined extent of change was 0.6 DAS28 points, 16 (29%) patients at T6 showed stable low disease activity of RA. When applying the DAS28 baseline score at all measurements (DAS28(T0)≤3.2, DAS28(T3)≤3.2, and DAS28(T6)≤3.2), the same 16 (29%) patients showed stable RA.

The result of assessing about 39% of patients as having stable, low disease activity of RA might be regarded as remarkable in a disease like RA. Furthermore, as the intention is to include these patients in substitution based, shared care treatment, this finding becomes even more important as the number of patients with RA treated at a rheumatology outpatient department increases.

The interval of three months between measurements was derived from medical practice, in which patients usually do not see the doctor more often than four times a year. To establish the optimal number of consultations for patients with stable RA, and for the purpose of stability assessment, further research into the length of the interval between measurements should be started.

The loss of one third of the group of patients needs attention. The patients with missing data were older, reported a higher mean DAS28 score, and had a higher mean global disease activity. Conceivably, these patients had more often non-stable RA. If data had been available for these non-stable patients, the ICCs would have been smaller.

With respect to the ICC, it may well be that identical scores are obtained in successive administrations, thus resulting in a

<table>
<thead>
<tr>
<th>Table 3</th>
<th>Scores of patients on DAS28 at baseline, six months later, and differences between scores at baseline and six months later</th>
</tr>
</thead>
<tbody>
<tr>
<td>T0*</td>
<td>T6†</td>
</tr>
<tr>
<td></td>
<td>≤3.2 but &gt;1.2</td>
</tr>
<tr>
<td>≤3.2</td>
<td>18</td>
</tr>
<tr>
<td>&gt;1.2</td>
<td>0</td>
</tr>
<tr>
<td>&gt;3.2 but ≤5.1</td>
<td>11</td>
</tr>
<tr>
<td>&gt;5.1</td>
<td>2</td>
</tr>
<tr>
<td>&gt;7.1</td>
<td>1</td>
</tr>
<tr>
<td>&gt;9.8</td>
<td>4</td>
</tr>
<tr>
<td>Total</td>
<td>29</td>
</tr>
</tbody>
</table>

* T0 measurement at start; T6 measurement six months after start.

<table>
<thead>
<tr>
<th>Table 4</th>
<th>Scores of patients on DAS28 at baseline (T0), differences between subsequent scores (T3–T0, T6–T0), and patients with stable, low disease activity of RA*</th>
</tr>
</thead>
<tbody>
<tr>
<td>T0</td>
<td>T3–T0≤1.2</td>
</tr>
<tr>
<td>n Cum%</td>
<td>n Cum%</td>
</tr>
<tr>
<td>≥1.32 but &lt;1.60</td>
<td>4</td>
</tr>
<tr>
<td>≥1.60 but &lt;2.40</td>
<td>13</td>
</tr>
<tr>
<td>≥2.40 but &lt;3.20</td>
<td>10</td>
</tr>
<tr>
<td>≥3.20 but &lt;4.00</td>
<td>22</td>
</tr>
<tr>
<td>≥4.00 but &lt;4.80</td>
<td>4</td>
</tr>
<tr>
<td>≥4.80 but ≤5.85</td>
<td>3</td>
</tr>
</tbody>
</table>

* DAS28(T0)≤3.2 and DAS28(T6)–DAS28(T0)≤1.2.
high value for the ICC, but that the actual units checked differ greatly. Based on the ICCs of the response criteria, a group of patients with stable disease was identified.

In conclusion, this study shows the feasibility of assessing disease activity of outpatients with RA. Although developed to measure response we applied the DAS28 to assess stability—that is, low disease activity of RA in patients for the purpose of including patients in another study. A minority of outpatients could be classified as having stable, low disease activity of RA. This finding suggests that RA is a suitable chronic disease to which to apply a substitution based model of care delivery.

ACKNOWLEDGEMENTS
This study was supported by a grant from Stimuleringsprogramma Gezondheidsonderzoek (Incentive Programme for Health Care Research) and Nationale Commissie Chronisch Zieken (National Committee Chronically Ill). The authors gratefully acknowledge the help of Yvonne van Eijk and Ilse Klein Goldewijk in measuring patients’ disease stability and their assistance with data processing.

Authors’ affiliations
H J M Vrijhoef, JP M Diederiks, C Spreeuwenberg, Department of Health Care Studies, University of Maastricht, The Netherlands
Sj Van der Linden, Department of Internal Medicine, Division of Rheumatology, University Hospital Maastricht, The Netherlands

REFERENCES
Applying low disease activity criteria using the DAS28 to assess stability in patients with rheumatoid arthritis

H J M Vrijhoef, J P M Diederiks, C Spreeuwenberg and Sj Van der Linden

Ann Rheum Dis 2003 62: 419-422
doi: 10.1136/ard.62.5.419

Updated information and services can be found at:
http://ard.bmj.com/content/62/5/419

These include:

References
This article cites 13 articles, 3 of which you can access for free at:
http://ard.bmj.com/content/62/5/419#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Connective tissue disease (4253)
Degenerative joint disease (4641)
Immunology (including allergy) (5144)
Musculoskeletal syndromes (4951)
Rheumatoid arthritis (3258)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/